New Test Mesothelioma – Showing the effectiveness of the pleura mesothelioma patients

mesothelioma asbestos-related cancer caused by asbestos exposure over a long period of time. Symptoms of mesothelioma May not become apparent for decades after first contact with asbestos. Thus, in general, are not detected until late stage after serious side effects begin to imagine. What is the diagnosis of pleural mesothelioma?

Mesothelioma is generally very difficult to diagnose because symptoms do not for a long time after the initial exposure to asbestos occurs. In most cases pleural mesothelioma is often mistakenly for flu and pneumonia or other more advanced disease makes it extremely difficult to diagnose and treat. What are the symptoms of pleural mesothelioma?

symptoms of pleural mesothelioma is a very non-specific, which makes it very difficult to diagnose in early stages and properly treated. Other symptoms May appear decades after exposure to asbestos . Some symptoms are: flatulence anemia severe abdominal pain and chest Coughing up blood, difficulty in swallowing, persistent fatigue, difficulty breathing, dry cough, weight loss What is this new challenge?

new test relationships of genes to predict which patients will benefit from pleural mesothelioma are several ways of treatment and surgical procedures has been developed by researchers from Birgham and Women’s Hospital in Boston, Massachusetts. This test has proved its effectiveness in predicting the outcome in postoperative patients pleural mesothelioma – this is really very important progress in diagnosis and treatment of mesothelioma. As a test B?

gene ratio test is used to analyze the relative levels of expression of four genes involved in malignant mesothelioma . Researchers believe that there is a need to develop a molecular test that can predict the outcome of the operation due to lack of electricity means of assessing prognosis in determining which patients will benefit from therapy, surgery trimodality mesothelioma. How effective is this test?

researchers trimodality treatment that includes chemotherapy and radiation with surgical resection leads to increased life expectancy than non-surgical therapy in patients with malignant pleural mesothelioma . Although this treatment is effective in higher survival rate is only useful for about 50 percent of malignant pleural mesothelioma patients, this means that the remaining 50 percent of patients who could benefit from this test. In general, the test is in effect a new development in determining whether a patient will see improvement mesothelioma prognosis . The survival of this test?

survival for patients receiving therapy trimodality is about one to two years. However, about 20 percent of patients survive up tri fifteen years. This significant increase in survival, of course, good news for patients who May be genetically more likely to benefit from this aggressive new approach to treatment. Given the positive outcome of this test, the researchers insist on this test to become a common practice in the diagnosis and treatment planning for patients pleural mesothelioma . How reliable is this test?

According to researchers from its own tests show that it can be performed on samples obtained by minimally invasive biopsy is performed prior to major surgery . Tests also showed that it can be used as a reliable source to help inform clinical decisions about how to perform basic operations trimodal therapy or in addition to accurately predicting the postoperative outcome. development of new drugs and treatments pleural mesothelioma to give hope to people suffering from mesothelioma and their loved ones. We have great hope that these new tests will never be 100 percent effective in treating this disease at all stages.